Skip to content

AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020
9.69 -0.78 -7.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

About AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Founded
2012
CEO
Dr. Carl L.G. Hansen, PhD
Employees
562
Headquarters
Vancouver, British Columbia, Canada
Fiscal year end
12-31
Website
abcellera.com

Company profile

Exchange
US
Symbol
ABCL
Market-cap rank
#2215
Listing date
2020-12-11
Market cap
3.16B
Float cap
2.17B
Shares out
326.62M
Float shares
224.45M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.

AbCellera Biologics discussion 0 comments

Add a comment